TITLE:
RNA-Loaded Dendritic Cell Cancer Vaccine

CONDITION:
Renal Cell Carcinoma

INTERVENTION:
MB-002

SUMMARY:

      The purpose of this trial is to examine the safety, feasibility, immunological response, and
      clinical antitumor activity of administering a dendritic cell vaccine to patients with
      metastatic renal cell carcinoma.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Have a new diagnosis of metastatic renal cell carcinoma;

          -  Must be at least 18 years or older;

          -  Have a scheduled unilateral nephrectomy;

          -  ECOG of 0 or 1;

          -  Free of brain metastases by CT or MRI;

          -  Normal renal function in contralateral kidney;

          -  Male or non-pregnant/non-lactating female on appropriate birth control methods while
             on study;

          -  Clinically acceptable screening results.

          -  No immunosuppressive therapy not limited to corticosteroids (including topical
             steroids or steroid containing inhalers), azathioprine cyclosporine two months prior
             to study entry;

          -  No active autoimmune disease
      
